Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
BillionToOne, Inc.
BLLN
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $5.6B
$120.35
▼ -1.62%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$61.96 - $138.70
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 12.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary single-molecule DNA counting technology
- Non-invasive diagnostic capabilities with high accuracy
- Comprehensive product suite for prenatal and oncology applications
- Early mover advantage in precision molecular diagnostics
Bear Case
2 risks
- Average volatility.
- Growth premium of 3.4x vs Life Sciences Tools peers. Significant premium - requires sustained high growth to justify.
Growth
Strong growth ahead
Expanding adoption of non-invasive prenatal screening
Value
Growth premium of 3.4x vs Life Sciences Tools peers. Significant premium - requires sustained high growth to justify.
Momentum
Hot
+54.1% over 3m
Quality
Excellent
High-growth business (99% revenue growth, 70% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying BLLN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 6, 2026
Reported EPS of $0.34 vs $0.03 consensus (+981.8% surprise). Revenue of $108.4M vs $97.1M expected (+11.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+981.8%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
—
+79%
+84%
+117%
+113%
+84%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$36.2M
$38.4M
$45.1M
$59.0M
$66.6M
$83.5M
$96.1M
$108.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
16.6%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
$127.50
▲ +5.9% vs $120.35
Latest: Guggenheim · $125.00 · Jun 29, 2026
2 analysts covering